DEVICE FOR THE DELIVERY OF A LIQUID PHARMACEUTICAL AND/OR NUTRACEUTICAL GELATIN SPECIALITY TO PERSONS HAVING DIFFICULTY IN SWALLOWING
20230076203 · 2023-03-09
Inventors
Cpc classification
A61J1/067
HUMAN NECESSITIES
B65D2203/00
PERFORMING OPERATIONS; TRANSPORTING
International classification
Abstract
A device for delivering a liquid specialty of the pharmaceutical or food supplement type comprises a gelatin reservoir and a cap hermetically closing the reservoir. The device further comprises a tab arranged on the opposite side of the cap with respect to the reservoir, the tab being filled with gelatin.
Claims
1. A device for the delivery of a liquid formulation comprising a pharmaceutical or food, the device comprising: a soft gelatin reservoir; a cap hermetically closing the reservoir; and a tab arranged on an opposite side of the reservoir relative to the cap, the tab being filled with soft gelatin, wherein the tab has a cross-section less than or equal to a cross-section of the reservoir.
2. The device of claim 1, wherein the reservoir comprises a part having a substantially cylindrical shape closed on a side of the reservoir adjacent the tab, and closing on a side of the reservoir adjacent the cap by a part having a substantially conical shape.
3. The device of claim 2, wherein the device is molded from a single material.
4. The device of claim 3, wherein the is molded in one piece.
5. The device of claim 4, wherein the cap is filled with soft gelatin.
6. The device of claim 5, wherein the reservoir has a weakening line connecting the reservoir to the cap.
7. The device of claim 6, wherein the tab bears variable information.
8. The device of claim 7, wherein the reservoir contains, as a liquid formulation, a pharmaceutical composition comprising a molecule chosen from: paracetamol-acetaminophen, ibuprofen, melatonin, loratadine, vitamins, vitamin K, loperamide, nefopam, morphine, acetazolamide, dexamethasone, methotrexate, aprepitant, spironolactone, sildenafil, caffeine, midazolam, ranitidine, ondansetron, prednisone, ivermectin, vitamin D.
9. A method of delivering a liquid formulation to a person, comprising: providing a liquid delivery device including: a soft gelatin reservoir; a cap hermetically closing the reservoir, the reservoir containing the liquid formulation, the liquid formulation comprising a pharmaceutical or food; and a tab arranged on an opposite side of the reservoir relative to the cap, the tab being filled with soft gelatin, wherein the tab has a cross-section less than or equal to a cross-section of the reservoir; and using the liquid delivery device to deliver the liquid formulation to a person, wherein the delivery device is held by a user by way of the tab of the device.
10. The device of claim 1, wherein the device is molded from a single material.
11. The device of claim 10, wherein the device is molded in one piece.
12. The device of claim 1, wherein the cap is filled with soft gelatin.
13. The device of claim 1, further comprising a weakening line between the reservoir and the cap.
14. The device of claim 1, wherein the tab bears variable information.
15. The device of claim 1, wherein the reservoir contains, as a liquid formulation, a pharmaceutical composition comprising a molecule chosen from: paracetamol-acetaminophen, ibuprofen, melatonin, loratadine, vitamins, vitamin K, loperamide, nefopam, morphine, acetazolamide, dexamethasone, methotrexate, aprepitant, spironolactone, sildenafil, caffeine, midazolam, ranitidine, ondansetron, prednisone, ivermectin, vitamin D.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Other advantages and particularities of the disclosure will become apparent on reading the detailed description of implementations and embodiments, which are in no way limiting, with reference to the appended drawings, in which:
[0031]
[0032]
[0033]
[0034]
[0035]
DETAILED DESCRIPTION
[0036] Since the embodiments described hereinafter are not limiting in nature, it is possible in particular to consider variants of the disclosure that comprise only a selection of the features that are described, provided that this selection of features is sufficient to confer a technical advantage or to differentiate the disclosure from the prior art. This selection comprises at least one preferably functional feature without structural details, or with only a portion of the structural details if this part alone is sufficient to confer a technical advantage or to differentiate the disclosure from the prior art.
[0037] In the remainder of the description, elements having an identical structure or similar functions will be designated by the same references.
[0038] According to the present disclosure, the necessary dose of active ingredient is contained in the reservoir of the entire capsule. The soft gelatin capsule is, in this case, used as a single-dose system. It dispenses with the use of a syringe or pipette.
[0039] There are capsules that have a protrusion forming a cap, to be cut with a scissors-type implement. The use of scissors is prohibited in the hospital, as the opening could lead to contamination of the product.
[0040] Uni-doses in a similar form can be found in ophthalmology.
[0041] There are also unscrewing caps, generally used in cosmetics. Opening is a critical step. Indeed, opening of the capsule requires holding both the body of the capsule and the opening system. In doing so, the practitioner exerts pressure on the part containing the product, which thus comes out immediately. This has at least three drawbacks: [0042] the practitioner is in contact with the liquid, causing a risk of contamination or a risk for the practitioner; [0043] a volume of product is lost, not only by pressure from the practitioner on the reservoir, which causes the liquid to flow, but also by the cap, which also contains liquid that is necessarily lost; [0044] the volume of product lost results in an inaccuracy of the dose actually ingested by the patient.
[0045]
[0046] The device 1 comprises a soft gelatin reservoir 2 and a cap 3 hermetically closing the reservoir 2.
[0047] The cap 3 is molded in one piece with the rest of the device. The cap 3 consists solely of gelatin and is preferably solid. It does not contain any liquid, so that the product is entirely housed in the reservoir 2, which guarantees better observance of the quantity to be ingested.
[0048] The reservoir 2 is hermetic and contains a predetermined quantity of product.
[0049] The reservoir 2 has a weakening line 4 connected to the cap 3.
[0050] The cap 3 and the part of the reservoir 2 having the weakening line 4 form a system for opening the reservoir 2, making it possible to release the product without the use of tools. When the cap is turned or pulled by the user, the weakening line 4 is weakened and tends to break. As a result, the user has access to the product without having been in contact or brought an object into contact with the product, thus limiting any risk of contamination.
[0051] A tab 5, also called tail, is added to the device 1, placed on the opposite side of the reservoir 2 relative to the cap 3.
[0052] The tab 5 is filled with soft gelatin.
[0053] The entire device 1 is molded in the same material—which facilitates its manufacture—and in one piece. Thus, there is no risk of perforation or leakage subsequent to molding.
[0054] The tab 5 allows the practitioner and the parents to hold the device when delivering the product.
[0055] The tab 5 offers the possibility of a grip so as not to exert pressure on the reservoir part 2 at the time of opening and thus to prevent the liquid from exiting before delivery.
[0056] The tab 5 may bear variable information 6, for example, the name of the molecule or its code and dosage. It allows differentiation of the products, because the dosage and the name of the product can be noted on it, thus limiting any risk of confusion.
[0057] The molecule can be chosen from the following group: paracetamol, ibuprofen, melatonin, loratadine, vitamins, vitamin K, loperamide, nefopam, morphine, acetazolamide, dexamethasone, methotrexate, aprepitant, spironolactone, sildenafil, caffeine, midazolam, ranitidine, ondansetron, prednisone, ivermectin, vitamin D.
[0058] The variable information 6 on the tab 5 can be molded during the filling process. Other inscription means can be considered such as printing, engraving or adding a label.
[0059] The tab 5 makes it possible to make the device larger and wider in order to prevent any risk of suffocation, if a child were to swallow it.
[0060] The tab 5 makes it possible to hold the device during delivery, allowing a better grip and thus preventing the risk for the child of swallowing it.
[0061]
[0062] As before, the device 11 comprises a soft gelatin reservoir 12 and a cap 13 hermetically closing the reservoir 2. The reservoir 12 has a weakening line 14 connected to the cap 13. A tab 15, also called tail, is added to the device 11, placed on the opposite side of the reservoir 12 with respect to the cap 3.
[0063] The reservoir 12 comprises a portion 16 of substantially cylindrical shape disposed between a half-sphere 17 closing on the tab 15 side and a partial half-sphere 18 closing on the weakening line 14 side.
[0064] The partial half-sphere is closed on the side of the weakening line 14 by a part 19, preferably of substantially conical shape. The part 19 could be cylindrical or flared. The substantially conical-shaped part 19 can also make it possible to hold and close the reservoir 12, using one hand, while the weakening line 14 is weakened and tends to break due to the forces exerted, for example, by another hand, on the cap 13. The pressure applied to the conical or flared part will prevent any leakage of liquid and will guarantee that the final dose to be administered remains inside the reservoir.
[0065] The disclosure also relates to a device as described above in which the reservoir contains, as a liquid specialty, a pharmaceutical composition comprising a molecule chosen from: paracetamol-acetaminophen, ibuprofen, melatonin, loratadine, vitamins, vitamin K, loperamide, nefopam, morphine, acetazolamide, dexamethasone, methotrexate, aprepitant, spironolactone, sildenafil, caffeine, midazolam, ranitidine, ondansetron, prednisone, ivermectin, vitamin D.
[0066] As will be readily understood, the disclosure is not limited to the examples that have just been described, and numerous modifications may be made to these examples without departing from the scope of the invention as defined by the claims. In addition, the various features, forms, variants, and embodiments of the disclosure can be grouped together in various combinations as long as they are not incompatible or mutually exclusive.